Mission

Acute Kidney Injury (AKI) causes 1.7 million deaths per year globally. AKI is a frequent, clinical event occurring in up to 20% of all hospital patients. It is characterized by a rapid deterioration of renal function to varying degrees, and associated with an up to 15-fold higher risk of death. Patients with AKI have a significantly higher risk of developing chronic kidney disease.

Nephrolyx’s mission is to provide all diagnostic tools necessary to rapidly and precisely measure kidney function to enable earlier and more confident detection of AKI.

Vision

Nephrolyx IVD^× will be the standard test for every patient in every ICU worldwide to measure kidney function and detect AKI before it causes severe harm or death.

About Nephrolyx IVD^×

The standard of care for AKI detection in clinical routine is based on measuring biomarkers such as creatinine and cystatin C and takes 48 to 72 hours to yield clinically relevant results. This long delay leads to delayed therapeutic interventions. Nephrolyx IVDx is based on 30 years of clinical research on using the exogenous contrast agent Iohexol (common tradenames are Omnipaque, Accupaque) for measuring kidney function. Translating the scientific expertise into clinical routine, Nephrolyx IVDx consists of an industrially produced IVD kit for measuring Iohexol in serum on compatible UHPLC devices with UV or DAD detector and includes a software module for calculating GFR. Nephrolyx IVDx is flexible to support many common protocols for contrast agent measurement and allows measurement of kidney function within two to seven hours – less than one tenth of the standard timeline. Nephrolyx IVDx is cost effective, uses only common solvents and accessories and is easy to integrate into today’s clinical and laboratory workflows.